Astria Therapeutics ATXS

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.23 (-3.58%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Astria Therapeutics (ATXS)
    Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $6.19

    • Market Cap

      $349.33 Million

    • Price-Earnings Ratio

      -14.74

    • Total Outstanding Shares

      56.43 Million Shares

    • Total Employees

      59

    • Dividend

      No dividend

    • IPO Date

      June 25, 2015

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      22 boston wharf road, Boston, MA, 02210

    • Homepage

      https://www.astriatx.com

    Historical Stock Splits

    If you bought 55.607 shares of ATXS before March 18, 2004, you'd have 1 share today.
    Execution DateSplit Amount
    August 20, 20211-for-6 (Reverse Split)
    December 31, 20181-for-10 (Reverse Split)
    March 29, 2005104-for-100
    March 18, 2004103.75-for-100

    Cash Flow Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Cash Flow From Financing Activities$15.30 Million
    Net Cash Flow, Continuing$-6.48 Million
    Net Cash Flow From Operating Activities$-27.96 Million
    Net Cash Flow From Investing Activities, Continuing$6.19 Million
    Net Cash Flow From Investing Activities$6.19 Million
    Net Cash Flow From Operating Activities, Continuing$-27.96 Million

    Income Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Income/Loss From Continuing Operations Before Tax$-24.53 Million
    Net Income/Loss Available To Common Stockholders, Basic$-24.53 Million
    Diluted Average Shares$57.82 Million
    Basic Earnings Per Share$-0.42
    Basic Average Shares$57.82 Million
    Nonoperating Income/Loss$4.48 Million

    Comprehensive Income

    July 1, 2024 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-24.16 Million
    Other Comprehensive Income/Loss$-24.16 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss$-24.16 Million
    Other Comprehensive Income/Loss Attributable To Parent$376,000

    Balance Sheet

    July 1, 2024 to September 30, 2024
    MetricValue
    Liabilities$19.98 Million
    Wages$3.62 Million
    Cash$344.30 Million
    Noncurrent Liabilities$4.26 Million
    Noncurrent Assets$9.78 Million
    Other Current Liabilities$10.83 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ATXS from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      â“’ 2025 Financhle. All Rights Reserved.